3Année·
Avis pour $ILMN

Genetic engineering - progress on track 🚀?


From August 8, 2011 to the present day, the company's share price has increased by 1059%! With a current KBV of 14.1 as well as a P/E ratio of 94.7, these indicate a very high valuation. Nevertheless, do aspects speak for the company & is an entry worthwhile?🏆.


What does Illumina🏥 do?


🧬Manufacture the devices for gene sequencing.

According to a study by the UK Competition and Markets Authority, Illumina's equipment, reagents & spcial cells are applied in 80% - 90% of all sequencing


🛸"Next Generation Sequencing" Platform

Revolutionary drive in biology (the sequence of nucleotides in whole genomes or target regions of DNA or RNA at the highest level is hereby determined)


Reasons for further Wachstum💪🏼?


💰llumina's great contribution of cost reduction.

In 2005, the sequencing of a human genome had a price tag of about $10 million; today, the price tag is about $1000.


👨🏽‍⚕️Treibender Innovation boost

The fall in the price of DNA sequencing is causing the industry to become more innovative


💸Increasing profits

Average profit growth of 7% over the last five years, 11.6% within the last fiscal year


Did you already know the company or even have it in your portfolio🤪?

What do you think, will we still be able to gain percentages in this sector🧐?


-----------

Source: The Motley Fool, Investing.com

attachment
7
9 Commentaires

image de profil
I think the next innovation is in sequencing long strands of DNA. The Illumina methodology doesn't allow that. Illumina will rise steadily, but the huge yet another rise will not happen. Just like BioNtech
3
Voir toutes les 5 autres réponses
image de profil
The next illumina will come from the field of proteomics. ARK Invest has also understood this and is investing more in this area with its ARK G Fund. If you want to know the hot candidates, please have a look here: https://www.instagram.com/p/CSW4_v7Mj-e/?utm_medium=copy_link
2
Voir toutes les 2 autres réponses
Participez à la conversation